Doyle John Brendan 4

What Happened
John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics, reported a purchase of 10,000 common shares on April 16, 2026. The shares were acquired at $1.13 per share for a total cost of $11,300. The transaction is reported as code "P" (purchase).

Key Details

• Transaction date: 2026-04-16; Report filed: 2026-04-20 (filed within the standard two-business-day window).
• Price per share: $1.13; Shares acquired: 10,000; Total value: $11,300.
• Transaction code: P (purchase — open market or private purchase as reported).
• Shares owned after transaction: Not specified in the filing.
• Footnotes/other flags: None disclosed in the Form 4 excerpt provided.

Context
Insider purchases can be interpreted as a positive signal, but this acquisition is modest in dollar terms ($11.3k) and should be considered alongside other filings and company fundamentals. No indication of option exercise, gift, or tax withholding applies to this reported transaction.